宣肺逐瘀化痰法对低氧性肺动脉高压血管活性物质的影响  

The Effect of Ventilate Lung Remove Blood Stasis and Resolve phlegm Therapy on vasoactive substances in Hypoxic Pulmonary Hypertension Rats

作　　者：杨仁旭[1] 杨明高[2] 范俊德[2] 张旗[2] 陈红[2] 

机构地区：[1]成都中医药大学附属医院,四川成都610072 [2]成都中医药大学2003级,硕士研究生四川成都610075

出　　处：《四川中医》2006年第4期10-13,共4页Journal of Sichuan of Traditional Chinese Medicine

基　　金：四川省中医管理局基金课题(编号:2003-A18)

摘　　要：目的:探讨三拗芎葶合剂对低氧性肺动脉高压(HPH)大鼠血浆内皮素1(ET-1)、降钙素基因相关肽(CGRP)、血栓素B2(TXB2)、6-酮-前列环素1α(6-KETO-PGF1α)的影响。方法:取健康雄性SD大鼠50只,随机分为空白对照组、模型组、卡托普利组、中药高剂量组、中药低剂量组五组,除空白对照组外,将其余4组大鼠放入常压缺氧箱内缺氧造模5周,从第3周起各组分别用等量生理盐水、卡托普利溶液及三拗芎葶合剂灌胃3周,各组动物在同等条件下饲养。5周之后用右心导管法检测PASP、PADP、mPAP;用放免法检测ET-1、CGRP、TXB2、6-KETO-PGF(1α)。结果:实验显示模型组PASP、PADP、mPAP明显升高;中药高、低剂量组CGRP、6-KETO-PGF(1α)明显升高,ET-1、TXB2、PASP、PADP、mPAP明显降低。结论:三拗芎葶合剂能够通过升高大鼠血浆CGRP水平、6-KETO-PGF(1α)含量,降低TXB2、ET-1含量而防治肺动脉高压,并改善HPH大鼠血液的高凝状态。为宣肺逐瘀化痰法治疗肺动脉高压提供了试验依据。Objective： To explore the effect of mixture of San＇aotingxiong on ET-1, CGRP, TXB2, 6-KETO-PGF1α in hypoxic pulmonary hypertension rats. Methods： Fifty male SD rats were randomly divided into five groups： blank-control group, model group and captopril group, large-dosage Chinese herb group, small-dosage Chinese herb groupo Hypoxic pulmonary hypertension was established by exposing the rats {except the blank-control group） to normobaric hypexie condition for 5 weeks, from the third week, each group was separately treated with physioiogical saline, captopril liquor, mixture of San＇antingxiong of equal amount for 3 weeks.Each group was fed in equal, condition. After 5 weeks, PASP, PADP. mPAP were determined by right cardiac catheterization; ET-1, CGRP, TXB2. 6-KETO-PGF （1α） were determined by radioimmunoassay. Resuhs： PASP, PADP, mPAP of model group increase obviously, CGRP, 6-KETO-PGF （1α） of large-dosage Chinese herb group and small-dosage Chinese herb group increase obviously; ET-1, TXB2, PASP, PADP, mPAP of large-dosage Chinese herb group and small-dosage Chinese herb group decrease obviously. Conclusions： mixture of San＇aotingxiong can prevent and treat pulmonary hypertension and improve the high blood-coagulation state in hypexic puhnonary hypertension rats through raising the level of CGRP, 6-KETO-PGF （1α） in blood plasma, reducing the level of TXB2, ET-1. Thus provide the experimental evidence for ventilate lung remove blood stasis and resolve phlegm therapy treating pulmonary hypertension.

关 键 词：三拗芎葶合剂 低氧性肺动脉高压 内皮素1 降钙素基因相关肽6-酮-前列环素1α 血栓素B2 宣肺逐瘀化痰法 

分 类 号：R259.432[医药卫生—中西医结合] R285.5[医药卫生—中医内科学]